|
Diabetes, Vol 48, Issue 2 321-326, Copyright © 1999 by American Diabetes Association
Phosphorylated insulin-like growth factor binding protein 1 is increased in pregnant diabetic subjects
JM Gibson, M Westwood, FF Lauszus, JG Klebe, A Flyvbjerg and A White
Department of Medicine and School of Biological Sciences, University of Manchester, England, UK. mgibson@fs1.cmht.nwest.nhs.uk
During pregnancy, IGFs and their binding proteins (IGFBPs) are important
for the growth of fetal and maternal tissues. IGFBP-1 normally circulates
as a single, highly phosphorylated species (hpIGFBP-1). However, in
pregnancy there are lesser phosphorylated isoforms (lpIGFBP-1) with
decreased affinity for IGF-I, allowing for increased IGF bioavailability.
Because regulation of IGFBP-1 is abnormal in type 1 diabetes, we examined
the impact of this on IGFBP-1 and its phosphorylation status in diabetic
pregnancy. We assessed IGFBP-1 in relation to birth weight, maternal weight
gain, duration of diabetes, glycemic control, and the presence or absence
of retinopathy in 44 diabetic and 11 nondiabetic subjects. We found that in
type 1 diabetic patients there was a significant negative relationship
between hpIGFBP-1 and birth weight (r = -0.42, P < 0.01) and between the
ratio of hpIGFBP-1 to lpIGFBP-1 and birth weight (r = -0.38, P = 0.02) by
week 18 of gestation. Multiple regression analysis confirmed that hpIGFBP-1
was the best single predictor of birth weight (R2 = 0.3, P = 0.001) in
diabetic subjects using models including other parameters known to
influence fetal size. In contrast to hpIGFBP-1 levels, lpIGFBP-1 levels
were not associated with birth weight, but were significantly related to
initial maternal BMI and maternal weight throughout gestation in diabetic
subjects (r = -0.57, P < 0.001). hpIGFBP-1 levels were positively
related to duration of diabetes (r = 0.38, P < 0.01). Diabetic subjects
had significantly higher hpIGFBP-1 and lpIGFBP-1 levels than nondiabetic
subjects (hpIGFBP-1: 215 +/- 21 vs. 108 +/- 13 microg/l, P = 0.01;
lpIGFBP-1: 139 +/- 12 vs. 66 +/- 5 microg/l, P < 0.001), but the ratio
of hpIGFBP-1 to lpIGFBP-1 was similar in both groups (2.1 +/- 0.3
[diabetic] vs. 1.7 +/- 0.2 [nondiabetic], NS). In summary, maternal IGFBP-1
levels were higher in diabetic than in normal pregnancies. Diabetic
subjects with prolonged duration of diabetes and retinopathy had higher
total IGFBP-1 levels than those with shorter disease duration. Thus
hpIGFBP-1 in diabetic pregnancy is positively related to the duration of
diabetes and inversely related to fetal growth, with lpIGFBP-1 being
related to maternal weight and BMI. The ratio of hpIGFBP-1 to lpIGFBP-1 may
be a more robust indicator of fetal outcome, since it was consistent
between diabetic and nondiabetic subjects. Measurement of the different
phosphorylated isoforms of IGFBP-1 may increase the usefulness of IGFBP-1
as a predictor of fetal growth in both normal and diabetic pregnancy.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
F. F. Lauszus, J. G. Klebe, T. Bek, and A. Flyvbjerg
Increased Serum IGF-I During Pregnancy Is Associated With Progression of Diabetic Retinopathy
Diabetes,
March 1, 2003;
52(3):
852 - 856.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Heald, K.W. Siddals, W. Fraser, W. Taylor, K. Kaushal, J. Morris, R. J. Young, A. White, and J. M. Gibson
Low Circulating Levels of Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Are Closely Associated With the Presence of Macrovascular Disease and Hypertension in Type 2 Diabetes
Diabetes,
August 1, 2002;
51(8):
2629 - 2636.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Verhaeghe, A. Pintiaux, E. van Herck, G. Hennen, J.-M. Foidart, and A. Igout
Placental GH, IGF-I, IGF-Binding Protein-1, and Leptin during a Glucose Challenge Test in Pregnant Women: Relation with Maternal Body Weight, Glucose Tolerance, and Birth Weight
J. Clin. Endocrinol. Metab.,
June 1, 2002;
87(6):
2875 - 2882.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Krampl, N. A. Kametas, F. McAuliffe, A. M. Cacho-Zegarra, and K. H. Nicolaides
Maternal Serum Insulin-Like Growth Factor Binding Protein-1 in Pregnancy at High Altitude
Obstet. Gynecol.,
April 1, 2002;
99(4):
594 - 598.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Bajoria, M. J. Gibson, S. Ward, S. R. Sooranna, J. P. Neilson, and M. Westwood
Placental Regulation of Insulin-Like Growth Factor Axis in Monochorionic Twins with Chronic Twin-Twin Transfusion Syndrome
J. Clin. Endocrinol. Metab.,
July 1, 2001;
86(7):
3150 - 3156.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. F. LAUSZUS, J. G. KLEBE, and A. FLYVBJERG
Macrosomia Associated With Maternal Serum Insulin-Like Growth Factor-I and -II in Diabetic Pregnancy
Obstet. Gynecol.,
May 1, 2001;
97(5):
734 - 741.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.M. Gibson, J.D. Aplin, A. White, and M. Westwood
Regulation of IGF bioavailability in pregnancy
Mol. Hum. Reprod.,
January 1, 2001;
7(1):
79 - 87.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1999 by the American Diabetes Association.
|
|
| |
|